Oncology

As of 24 Jan, 2025

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
ONO-4059	BTK inhibitor	Primary central nervous system lymphoma						JP・KR・TW	In-house
								US
		Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma						JP
QINLOCK／ripretinib	KIT inhibitor	Gastrointestinal Stromal Tumor 2nd KIT Exon 11+17/18						NA・SA・EU・AU・KR・TW	In-house(Deciphera)
DCC-3116	ULK inhibitor	Solid tumor（with sotorasib）						US	In-house(Deciphera)
		Advanced Malignancies（with ripretinib）						US
DCC-3084	Pan-RAF inhibitor	Advanced Malignancies						US	In-house(Deciphera)
DCC-3009	Pan-KIT inhibitor	Gastrointestinal Stromal Tumor						US	In-house(Deciphera)
ONO-7475	Axl/Mer inhibitor	Pancreatic cancer ★						JP	In-house
		EGFR mutation-positive non-small cell lung cancer						JP
ONO-4685	PD-1 x CD3 bispecific antibody	T-cell lymphoma						JP・US	In-house
ONO-4578	PG receptor (EP4) antagonist	Gastric cancer ★						JP・KR・TW	In-house
		Colorectal cancer ★						JP
		Non-small cell lung cancer ★						JP
		Hormone receptor-positive, HER2-negative breast cancer						JP
ONO-7914	STING agonist	Solid tumor ★						JP	In-house
ONO-7018	MALT1 Inhibitor	Non-Hodgkin lymphoma, Chronic lymphocytic leukemia						JP・US	Chordia
ONO-8250	iPSC-derived HER2 CAR T-cell therapy	HER2-expressing Solid tumor						US	Fate
ONO-7428	Anti-ONCOKINE-1 antibody	Solid tumor						JP	NEX-I

★Combination with Nivolumab

Other than oncology

As of 24 Jan, 2025

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
DCC-3014／vimseltinib	CSF-1R inhibitor	Tenosynovial Giant Cell Tumor*						NA・EU	In-house(Deciphera)
ONO-4059	BTK inhibitor	Pemphigus						JP	In-house
ONO-2808	S1P5 receptor agonist	Multiple System Atrophy						JP・US	In-house
DCC-3014／vimseltinib	CSF-1R inhibitor	chronic Graft Versus Host Disease						US	In-house(Deciphera)
ONO-4685	PD-1 x CD3 bispecific antibody	Autoimmune disease						JP・EU	In-house
ONO-1110	Endocannabinoid regulation	Postherpetic Neuralgia						JP	In-house
		Fibromyalgia						JP
		Hunner Type Interstitial Cystitis						JP
		Major Depressive Disorder						JP
		Social Anxiety Disorder						JP
ONO-2020	Epigenetic Regulation	Alzheimer’s Disease						JP・US	In-house
		Agitation Associated with Dementia Due to Alzheimer's Disease						JP
ONO-4915	PD-1 x CD19 bispecific antibody	Autoimmune disease						JP	In-house

* : FDA, EMA Filing accepted

NA : North America, SA : South America, AU : Australia, EU : European Country